Primary Effusion Lymphoma — Trials

Primary Effusion Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

14 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 7
Recruiting: 2
Ph III recruiting: 0
Growth YoY: —
Industry share: 14%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02823327	Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma	terminated	—	25	AIDS Malignancy ConsortiumNETWORK	1	May 11, 2025	clinicaltrials
NCT00183976	Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas	terminated	Phase 2	15	University of Southern CaliforniaOTHER	1	May 22, 2014	clinicaltrials